Publication:

Cell therapies for hematopoietic failure in trauma hemorrhagic shock

Traumatic hemorrhagic shock (T/HS) is clinically associated with hematopoietic failure (HF). HF in T/HS patients is characterized by an increase in the levels of norepinephrine, cytokines, granulocyte-colony stimulating factor and peripheral blood hematopoietic progenitor cells, as well as a decrease in the expression of erythropoietin receptors. Reducing cytokines, vascular dysfunction, tissue damage, apoptosis and HF may be possible with cell-based therapy. Regulatory T cells, mesenchymal stem cells, bone marrow mononuclear cells and induced pluripotent stem cell-derived hematopoietic progenitor cells are all cell-based treatments that have shown promise in improving the prognosis of patients with T/HS by ameliorating bone marrow malfunction or HF. Here, we discuss the latest cell-based therapy approaches for treating HF in T/HS patients.